IRIS
LENCI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.189
AS - Asia 3.231
EU - Europa 1.289
SA - Sud America 378
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 13.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.101
SG - Singapore 1.973
CN - Cina 441
RU - Federazione Russa 311
BR - Brasile 308
VN - Vietnam 233
HK - Hong Kong 228
IT - Italia 206
IE - Irlanda 155
DE - Germania 134
GB - Regno Unito 102
FR - Francia 87
JP - Giappone 80
KR - Corea 76
IN - India 71
FI - Finlandia 66
CA - Canada 45
PL - Polonia 42
MX - Messico 31
SE - Svezia 30
AR - Argentina 29
UA - Ucraina 28
ES - Italia 23
AT - Austria 21
BD - Bangladesh 20
ID - Indonesia 20
NL - Olanda 20
ZA - Sudafrica 14
BE - Belgio 13
CZ - Repubblica Ceca 11
TR - Turchia 11
CH - Svizzera 10
LT - Lituania 10
EC - Ecuador 9
IQ - Iraq 9
IR - Iran 9
EG - Egitto 8
PK - Pakistan 8
VE - Venezuela 8
CO - Colombia 6
MA - Marocco 6
PY - Paraguay 6
CL - Cile 5
IL - Israele 5
KE - Kenya 5
AZ - Azerbaigian 4
EU - Europa 4
QA - Qatar 4
SA - Arabia Saudita 4
TM - Turkmenistan 4
TN - Tunisia 4
AU - Australia 3
DZ - Algeria 3
HN - Honduras 3
JO - Giordania 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
PE - Perù 3
PH - Filippine 3
SN - Senegal 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
CR - Costa Rica 2
DK - Danimarca 2
KH - Cambogia 2
KZ - Kazakistan 2
NG - Nigeria 2
NO - Norvegia 2
RO - Romania 2
RS - Serbia 2
SV - El Salvador 2
TW - Taiwan 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 13.144
Salva come PNG Salva come JPEG
Città #
Wilmington 1.914
Houston 1.572
Singapore 730
Woodbridge 520
Fairfield 369
Ashburn 367
New York 361
San Jose 338
Chandler 321
Hong Kong 219
Beijing 182
Dublin 134
The Dalles 126
Seattle 118
Los Angeles 117
Cambridge 115
Medford 105
Council Bluffs 104
Santa Clara 94
Ann Arbor 91
Elk Grove Village 86
Ho Chi Minh City 86
Tokyo 76
Rome 72
Hanoi 51
Lauterbourg 49
Helsinki 48
Lawrence 48
Munich 47
Buffalo 40
Moscow 39
São Paulo 33
Nuremberg 31
Orem 30
San Diego 30
Warsaw 30
London 28
Menlo Park 26
Chicago 25
Dallas 25
North Bergen 23
Seoul 23
Montreal 22
Chennai 21
Dearborn 21
Frankfurt am Main 18
Palo Alto 18
Mexico City 17
Redondo Beach 17
Brooklyn 15
Atlanta 14
Creede 14
Denver 14
Engelhard 14
Jakarta 14
Stockholm 13
Brussels 12
Jacksonville 12
Lappeenranta 12
Miami 12
Phoenix 12
Shanghai 12
Vienna 12
Milan 11
Washington 11
Boardman 10
Poplar 10
Redwood City 10
Rio de Janeiro 10
San Francisco 10
Biên Hòa 9
Colorado Springs 9
Johannesburg 9
Manchester 9
Nanjing 9
Toronto 9
Hangzhou 8
Hefei 8
Brno 7
Chandigarh 7
Da Nang 7
Hải Dương 7
Suzhou 7
Haiphong 6
Hounslow 6
Madrid 6
Mumbai 6
Salt Lake City 6
Amsterdam 5
Curitiba 5
Nairobi 5
New Delhi 5
Norwalk 5
Porto Alegre 5
Ribeirão Preto 5
Shenzhen 5
St. George 5
Tampa 5
Tehran 5
Bari 4
Totale 9.425
Salva come PNG Salva come JPEG
Nome #
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 519
Pitfalls in the reporting of upper endoscopy features in cirrhotic patients 446
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 429
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 412
Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients 366
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study 344
An unusual duodenal polyp causing anemia in a liver-transplanted patient 344
Clinical Operational Tolerance and Immunosuppression Minimization in Kidney Transplantation: Where Do We Stand? 339
Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant 339
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 333
Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? 327
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 308
Trans-splenic Embolization Plus Partial Splenic Embolization for Management of Variceal Bleeding Due to Left-Sided Portal Hypertension 301
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 299
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 297
Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: differences and similarities along the path 296
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 287
Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study 271
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 257
Dual role of bile acids on the biliary epithelium: Friend or foe? 233
Platelets and hepatocellular cancer: Bridging the bench to the clinics 221
Liver Transplantation For HDV/HBV Coinfection In Italy: An Intention-To-Treat Analysis Of Long-Term Outcomes 218
Domino liver transplantation: Where are we now? 211
Evaluation of liver fibrosis in cirrhotic patients: comparison between elastosonography and fibroscan 209
Liver transplantation for hepatocellular carcinoma: Where do we stand? 207
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: A real-life strategy 203
Vascular anomalies of the celiac trunk and implications in treatment of HCC with TACE. Description of a case and review of the literature 199
De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature 198
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study 159
Cholangiocarcinoma: Bridging the translational gap from preclinical to clinical development and implications for future therapy 149
Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient 135
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 135
Moving forward in the treatment of cholangiocarcinoma 127
Serum Levels of Granulocyte-Macrophage-colony-stimulating Factor and Stem-cell Factor During Liver Regeneration after Partial Hepatectomy in Humans 118
Current strategies to minimize ischemia-reperfusion injury in liver transplantation: a systematic review 112
Natremia and liver transplantation: The right amount of salt for a good recipe 108
Chronic rejection after liver transplantation: Opening the Pandora's box 102
Molecular mechanisms linking risk factors to cholangiocarcinoma development 101
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 100
Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? 99
Fairness and pitfalls of the Italian waiting list for elective liver transplantation: The ECALITA registry study 99
Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury 98
COVID-19 in normal, diseased and transplanted liver 96
Gastrointestinal endoscopy in cirrhotic patient: Issues on the table 95
Electronic Outpatient Referral System for Liver Transplant Improves Appropriateness and Allows First Visit Triage 94
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 93
The acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer in vivo, impairs HBsAg secretion and affects its structural stability in vitro 92
Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor 92
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 90
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 90
Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5) 89
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 85
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 83
Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins 83
Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation 82
Secondary bile acids and the biliary epithelia: The good and the bad 82
Towards tolerance in liver transplantation 82
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 78
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 76
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 75
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 74
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 74
Role of Cone-Beam CT in the Intraprocedural Evaluation of Chemoembolization of Hepatocellular Carcinoma 72
null 71
Sequence of events leading to primary biliary cholangitis 70
Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation 69
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 68
HDV INFECTION IS STABLE IN CENTRAL ITALY ACROSS THE LAST TWO DECADES AND IS CHARACTERIZED BY THE CIRCULATION OF MULTIPLE HDV SUB-GENOTYPES 1 WITH A DIFFERENT PRO-INFLAMMATORY POTENTIAL 68
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 68
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 67
New strategies on management of hepatitis B virus after liver transplantation: complete and sustained weaning of HBV prophylaxis in a selected cohort of patients transplanted due to HBV-related cirrhosis 67
Development of Autoimmune Hepatitis after COVID-19 Infection in Vaccinated Women 66
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 66
THE ENRICHMENT OF POSITIVELY CHARGED AMINO ACIDS IN HBsAg C-TERMINUS IMPAIRS HBsAg SECRETION, AFFECTS ITS STRUCTURAL STABILITY AND IS CORRELATED WITH HBV-INDUCED LIVER CANCER. 65
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation 65
Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: A case report 64
Benign disease and unexpected histologocal findings after pancreaticoduodenectomy: The role of endoscopic ultrasound fine needle aspiration 64
Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity. 61
The Effects of Sustained Immunosuppression Withdrawal After Liver Transplantation on Metabolic Syndrome 58
Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: A pilot study 58
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 54
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 52
Use of intravascular ultrasound to improve diagnosis and treatment of transjugular intrahepatic portosystemic shunt dysfunction in patients in the long-term follow-up 51
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 51
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 51
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 51
Sarco-Model: a score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation 50
Saline Contrast Echocardiography in Patients With Hepatopulmonary Syndrome Awaiting Liver Transplantation 44
null 42
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance 28
null 22
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 20
HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential. 19
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 17
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 15
An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity 15
Intra-hepatic HDV replicative activity can be sustained by HBsAg production from HBV-DNA integration and can modulate virological response to bulevirtide 14
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA 14
Totale 13.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202157 0 0 0 0 0 0 0 0 0 0 30 27
2021/2022606 28 62 18 27 9 72 46 24 71 60 38 151
2022/2023805 75 79 46 88 80 156 72 72 73 11 32 21
2023/2024478 60 16 43 13 62 135 9 14 14 54 3 55
2024/20252.589 56 347 205 105 28 183 169 60 172 181 622 461
2025/20264.027 426 147 416 421 364 337 512 485 543 370 6 0
Totale 13.557